Literature DB >> 3814817

Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases.

J L Liesveld, J M Rowe, M A Lichtman.   

Abstract

One hundred-nine cases of autoimmune hemolysis were reviewed to determine the frequency of reticulocytopenia, the state of the erythroid marrow in reticulocytopenic cases, and the course of reticulocyte production indices with time and glucocorticoid treatment. The mean hematocrit at presentation was 24 mL/dL, but 30% of cases had an initial hematocrit less than 20 mL/dL. Median reticulocyte percentage at diagnosis was 9%, and median reticulocyte production index was 2.8 times basal. Twenty percent of cases had an initial reticulocyte count less than 4%, and 37% had an initial reticulocyte production index less than 2.0 times basal. These reticulocytopenic patients were nearly evenly distributed between warm and cold antibody-mediated cases and between primary and secondary cases. Fifty-four percent of reticulocytopenic cases had a bone marrow examination during hospitalization. Three-fourths of these marrows showed erythroid hyperplasia, and erythroid hypoplasia was seen in only one case. Eighty-eight cases had serial reticulocyte measurements, and in only 15% of patients did the reticulocyte production index remain less than 2.0 times basal. Thus, in most cases, the initially low reticulocyte production index may represent a lag in marrow responsiveness to hemolytic stress. In cases with persistent reticulocytopenia, ineffective erythropoiesis is suggested by the frequency of marrow erythroid hyperplasia. In the cases that were initially reticulocytopenic and demonstrated an increase in reticulocyte production index, the magnitude of this increase was significantly greater in glucocorticoid-treated patients than in those not so treated, indicating that a glucocorticoid sensitive component exists in the marrow erythropoietic response to hemolysis. Awareness of the frequency of an initial reticulocytopenia in cases of autoimmune hemolysis may be important in initial diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3814817

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Autoimmune hemolytic anemia.

Authors:  Anita Hill; Quentin A Hill
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  A rare case of autoimmune haemolytic anaemia due to warm IgA autoantibodies with reticulocytopenia.

Authors:  F Lussana; S Caberlon; S Altomare; M Lanfredini; M Cattaneo
Journal:  Intern Emerg Med       Date:  2007-07-18       Impact factor: 3.397

3.  Diagnosis and management of newly diagnosed childhood autoimmune haemolytic anaemia. Recommendations from the Red Cell Study Group of the Paediatric Haemato-Oncology Italian Association.

Authors:  Saverio Ladogana; Matteo Maruzzi; Piera Samperi; Silverio Perrotta; Giovanni C Del Vecchio; Lucia D Notarangelo; Piero Farruggia; Federico Verzegnassi; Nicoletta Masera; Paola Saracco; Silvia Fasoli; Maurizio Miano; Gabriella Girelli; Wilma Barcellini; Alberto Zanella; Giovanna Russo
Journal:  Blood Transfus       Date:  2016-12-16       Impact factor: 3.443

Review 4.  Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review.

Authors:  Peter Valent; Klaus Lechner
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 5.  Treatment of autoimmune hemolytic anemias.

Authors:  Alberto Zanella; Wilma Barcellini
Journal:  Haematologica       Date:  2014-10       Impact factor: 9.941

6.  Plasmapheresis in a child with cold antibody autoimmune hemolytic anemia: case report.

Authors:  Zeynep Canan Özdemir; Özcan Bör; Ener Çağrı Dinleyici; Eylem Kıral
Journal:  Turk Pediatri Ars       Date:  2017-09-01

Review 7.  Red blood cell population dynamics.

Authors:  John M Higgins
Journal:  Clin Lab Med       Date:  2014-12-18       Impact factor: 1.935

Review 8.  Fatal fulminant autoimmune haemolytic anaemia associated with tolmetin use and gastric carcinoma. Case report and literature review.

Authors:  J R Larsen; J W Becher
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

9.  Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Ulla Derhaschnig; Nina Buchtele; Christian Sillaber; Michael Fillitz; Thomas M Schenk; Shirley D'Sa; Ronwyn Cartwright; James C Gilbert; Bernd Jilma; Ulrich Jaeger
Journal:  Blood Adv       Date:  2020-03-24

10.  Concurrent poststreptococcal glomerulonephritis and autoimmune hemolytic anemia.

Authors:  Larry A Greenbaum; Bryce A Kerlin; Scott Van Why; Rowena C Punzalan; Beth A Trost; Cynthia G Pan; J Paul Scott
Journal:  Pediatr Nephrol       Date:  2003-10-30       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.